Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy (Q33970538)

30 July 2017

1 reference

title

Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy (English)

1 reference

30 July 2017

1 reference

1 reference

Oh WK

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

88

1 reference

30 July 2017

issue

12 Suppl

1 reference

30 July 2017

page(s)

3015-3021

1 reference

30 July 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

The biology of hormone refractory prostate cancer. Why does it develop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Clinical trials in relapsed prostate cancer: defining the target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Estrogen receptor-beta: implications for the prostate gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Mechanisms of action and clinical uses of estramustine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3015%3A%3AAID-CNCR18%3E3.0.CO%3B2-M

10.1002/1097-0142(20000615)88:12+<3015::AID-CNCR18>3.0.CO;2-M

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference